ClinicalTrials.gg
Status unknownNCT05125523Updated Jan 25, 2022

A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors

A Phase 1 interventional study of Sirolimus for Injection (Albumin Bound) in Advanced Solid Tumors, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-25.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
264
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to estimate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of Sirolimus for Injection (Albumin Bound) in patients with solid malignancies.

Read the detailed description

This study will be conducted in two stages.

Stage 1: To evaluate the safety and tolerability of Sirolimus for Injection (Albumin Bound) in patients with advanced tumors, determine the MTD and RP2D. The dose escalation scheme using the accelerated titration design for dose 1 and the rolling-six design for the remaining doses.

Stage 2: To preliminarily assess the antitumor activity of Sirolimus for Injection (Albumin Bound). Patients will be assigned to different cohorts based on their tumor type.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Sirolimus for Injection (Albumin Bound)
03

In context

Lead sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is the lead sponsor of 167 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years (inclusive), no gender limitation.
  2. Patients must have a or cytologically confirmed advanced or tumor for which no effective standard therapy is available, or have failed or been intolerant to standard therapies.
  3. At least one per version 1.1.
  4. (ECOG) Performance Status (PS) of 0 to 2.
  5. of ≥3 months.
  6. Suitable organs and hematopoietic function should be available. Laboratory tests during screening should meet the appropriate criteria.
  7. Signed form.

Exclusion criteria

Exclusion Criteria:

  1. Prior anticancer treatment or participation in another clinical study within 4 weeks (or 5 half-lives of the treated drug, whichever is longer) prior to the first dose of study drugs.
  2. Patients who have undergone major surgery within 4 weeks prior to starting study treatment, or who have not fully recovered from previous surgery.
  3. Unresolved toxicities from prior therapy greater than Grade 1 as per (CTCAE) (except alopecia or any other toxicity without safety risks as judged by the investigator).
  4. History of serious cardiovascular disease.
  5. Central nervous system or meningeal metastasis with clinical symptoms, or other evidence that the patient's central nervous system metastasis or meningeal metastasis has not been controlled, and the investigator judges it to be unsuitable for inclusion.
  6. Known prior to study drugs or any component in their formulations.
  7. Prior treatment with any mTOR inhibitor.
  8. Has received a live or within 30 days prior to consent.
  9. Uncontrollable active infection (CTCAE v5.0 ≥grade 2).
  10. Use of strong inhibitors and inducers of within 2 weeks prior to receiving the first dose of study drug and still need to continue using this class of drug.
  11. History of diseases, immunodeficiency, including positive, or other acquired, congenital immunodeficiency, or organ transplant history.
  12. -positive with HBV viral load (VL) ≥1000 IU/mL; Virus (HCV)-positive; Anti-treponema pallidum positive.
  13. Women of , or men whose partners are women of childbearing age, have not agree to use highly effective methods of during dosing and for 6 months after study drug discontinuation; female patients has a positive serum pregnancy test within 7 days prior to receiving the first dose of study medication; lactating female.
  14. Has history of other serious diseases judged by the investigator, which will threaten the safety of patients or interfere the study compliance, or other reasons are not suitable for participating in the study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
264 participants (estimated)

Study arms

  • Experimental
    Sirolimus for Injection (Albumin Bound)

    Stage 1:Multiple doses of Sirolimus for Injection (Albumin Bound) will be administered intravenously. Stage 2:RP2D of Sirolimus for Injection (Albumin Bound) as determined during stage 1 will be administered intravenously.

    Drug: Sirolimus for Injection (Albumin Bound)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    Time frame: Up to 3 years

  2. Dose-Limiting Toxicities (Stage 1)

    Time frame: Cycle 1 (Up to 28 days)

  3. Maximum tolerated dose (Stage 1)

    Time frame: Up to 1.5 years

  4. Recommended phase 2 dose (Stage 1)

    Time frame: Up to 1.5 years

  5. Overall response rate (Stage 2)

    Time frame: Up to 3 years

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC)

    Time frame: Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)

  2. Peak concentration (Cmax)

    Time frame: Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)

  3. Peak time (Tmax)

    Time frame: Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)

  4. Distribution volume (Vz)

    Time frame: Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)

  5. Elimination half-life (t1/2)

    Time frame: Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)

  6. Clearance (CL)

    Time frame: Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)

  7. Disease Control Rate

    Time frame: Up to 3 years

  8. Duration of Response

    Time frame: Up to 3 years

  9. Progression-free Survival

    Time frame: Up to 3 years

  10. 4ebp-1 phosphorylation level in blood samples

    Time frame: Up to 168 hours post dose

  11. S6K phosphorylation level in blood samples

    Time frame: Up to 168 hours post dose

  12. TSC1/2 status in tumor samples

    Time frame: Day 1 of cycle 1

  13. PTEN status in tumor samples

    Time frame: Day 1 of cycle 1

  14. PIK3CA status in tumor samples

    Time frame: Day 1 of cycle 1

07

Study locations

1 of 1 sites recruiting
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2021 (actual). Primary completion is estimated for Jun 2024, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2021
First posted
Nov 18, 2021
StartActual
Dec 28, 2021
Primary completionEst.
Jun 2024
CompletionEst.
Nov 2024
Last update
Jan 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05125523
Responsible party
Sponsor
First posted
Nov 18, 2021
Start date
Dec 28, 2021
Primary completion
Jun 2024 (estimated)
Completion
Nov 2024 (estimated)
Last update
Jan 25, 2022

Study contacts

Xuekun Yao
Contact
yaoxuekun@mail.ecspc.com
0311-67808678
Yue Huang
Contact
huangyue@mail.ecspc.com
Jihui Hao
principal investigator · Tianjin Medical University Cancer Institute and Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion